Target intelligence / Profile preview

Carbonic anhydrase 9 (CA9)

Target
CA9
Molecular classification
Enzyme, Other
01

Overview

Carbonic anhydrase 9 (CA9, also known as CA-IX or G250) is a transmembrane zinc metalloenzyme that catalyzes the reversible hydration of carbon dioxide into bicarbonate and protons. It is highly overexpressed in many solid tumors, particularly clear cell renal cell carcinoma (ccRCC), under the control of hypoxia-inducible factor 1-alpha (HIF-1α) in response to tumor hypoxia. In contrast, its expression in normal tissues is highly restricted, primarily confined to the gastrointestinal tract. CA9 plays a critical role in tumor pH regulation, driving extracellular acidification and maintaining a neutral intracellular pH, which promotes cancer cell survival, invasion, metastasis, and resistance to chemotherapy and radiation. Because of its tumor-specific expression and cell-surface localization, CA9 is a highly attractive therapeutic and diagnostic target. Therapeutic strategies include small-molecule inhibitors (such as SLC-0111) that block its catalytic activity, monoclonal antibodies (such as girentuximab) that trigger antibody-dependent cellular cytotoxicity, and radiolabeled conjugates (such as 89Zr-DFO-girentuximab and 177Lu-girentuximab) for non-invasive PET imaging and targeted radionuclide therapy.

Other names
Carbonic anhydrase IXCA-IXCAIXG250Membrane antigen MNRenal cell carcinoma-associated antigen G250pMW1P54/58Ngp200Renal cell carcinoma-associated cell-surface antigen
02

Mechanism of action

Carbonic anhydrase inhibition, targeted radiopharmaceutical imaging, targeted radionuclide therapy, and antibody-dependent cellular cytotoxicity (ADCC).

03

Biological functions

pH regulationCell proliferationCell migrationCell survivalOther
04

Disease associations

CancerOther
05

Safety considerations

Systemic toxicity due to off-target inhibition of other carbonic anhydrase isoforms such as CA IIGastrointestinal toxicity due to low-level expression in gastric and gallbladder mucosaMyelosuppression associated with radiolabeled therapiesImmunogenicity of monoclonal antibodies
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

Carbonic anhydrase 9 expressionHypoxia-inducible factor 1-alpha expressionTumor hypoxia

Beyond the preview

Go deeper on Carbonic anhydrase 9 (CA9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carbonic anhydrase 9 (CA9).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call